Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | PTPRC | P08575 | 1/20 | 0.35 |
| ▸ | PTPRF | P10586 | 1/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505612 | 0.91 | PTGS2 (0.40) | PTGS2PTPN1PTPRCPTPRFCDC25B | |
| SCHEMBL1963482 | 0.84 | PTGS2 (0.39) | PTGS2PTPN1PTPRCPTPRFCDC25B | |
| SCHEMBL29073846 | 0.73 | PTGS2 (0.41) | PTGS2PTPN1PTPRCPTPRFCDC25B | |
| SCHEMBL29644614 | 0.72 | PTPN1 (0.38) | PTGS2PTPN1PTPRCPTPRFCDC25B | |
| SCHEMBL5379529 | 0.72 | PTPN1 (0.35) | PTGS2PTPN1PTPRCPTPRFCDC25B | |
| SCHEMBL10713148 | 0.69 | HTR1A (0.38) | PTGS2PTPN1PTPRCPTPRFCDC25B | |
| SCHEMBL4476575 | 0.69 | PTGS2 (0.56) | PTGS2PTPN1PTPRCPTPRFCDC25B | |
| SCHEMBL8754990 | 0.68 | PTGS2 (0.43) | PTGS2PTPN1PTPRCPTPRFCDC25B | |
| Phosphine SCHEMBL1505614 | 0.68 | POLB (0.34) | PTPN1PTPRCPTPRFCDC25BL3MBTL1 | |
| SCHEMBL161475 | 0.68 | ROCK2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | US | disclosed |
| WO-2011024004-A1 | HETEROCYCLIC UREA DERIVATIVES USEFUL FOR TREATMENT OF BACTERIAL INFECTION | ASTRAZENECA AB (SE) | 2011-03-03 | — | — | WO | disclosed |
| EP-2262801-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | AstraZeneca AB (SE) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009106885-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | UROD, UMPS, SLC14A1 | PTGS2 1659/4885PTPN1 4375/4885PTPRC 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.